{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:39:28Z","timestamp":1792643968682,"version":"4.5.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Managing patients with suspected heparin-induced thrombocytopenia (HIT) poses significant clinical challenges. Limited evidence exists on how management decisions impact clinical outcomes, leading to treatment recommendations based on low-certainty evidence. This study aimed to evaluate the treatment strategies and clinical outcomes of patients with suspected HIT in a contemporary multicenter cohort. We conducted a prospective, multicenter cohort study including consecutive patients with suspected HIT from 11 centers. Patients were stratified into 3 groups: (1) HIT confirmed, (2) HIT-negative but heparin\/platelet factor 4 (PF4) antibody-positive, and (3) HIT-negative without antibodies. Clinical and laboratory data were systematically collected. HIT was diagnosed using the washed-platelet heparin-induced platelet activation test as the reference standard. Among 1393 patients (46% female, median age 67 years), HIT was confirmed in 119 (8.5%). Most patients were in intensive care (37%), or had undergone cardiac surgery (32%). Argatroban was the predominant treatment (70%), and platelet recovery occurred in 77% of patients with HIT. Among patients with HIT, subsequent venous thromboembolism occurred in 23%, arterial thromboembolism in 9%, major bleeding in 12.6%, and mortality in 18%, with no significant differences between anticoagulants. Treatment with argatroban, bivalirudin, or direct oral anticoagulants (DOACs) significantly reduced arterial thromboembolism risk. Outcomes did not differ between patients who were HIT-negative with or without heparin\/PF4 antibodies. HIT, as well as the mere suspicion of HIT, remains a serious condition with a high risk of adverse outcomes, including death. Our findings provide further evidence supporting the effectiveness of DOACs, argatroban, and bivalirudin in reducing arterial thromboembolism risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016639","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:58:49Z","timestamp":1754337529000},"page":"5546-5555","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort"],"prefix":"10.1182","volume":"9","author":[{"given":"Henning","family":"Nilius","sequence":"first","affiliation":[{"name":"1Department of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Sinitsa","sequence":"additional","affiliation":[{"name":"1Department of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Dirk","family":"Studt","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology and Hematology, University and University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3135-4630","authenticated-orcid":false,"given":"Dimitrios A.","family":"Tsakiris","sequence":"additional","affiliation":[{"name":"3Diagnostic Haematology, Basel University Hospital, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8343-7336","authenticated-orcid":false,"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[{"name":"4Institut f\u00fcr Transfusionsmedizin, Universit\u00e4tsmedizin Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Mendez","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine, Kantonsspital Aarau, Aarau, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-8508","authenticated-orcid":false,"given":"Adrian","family":"Schmidt","sequence":"additional","affiliation":[{"name":"6Institute of Laboratory Medicine and Clinic of Medical Oncology and Hematology, Municipal Hospital Zurich Triemli, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter A.","family":"Wuillemin","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Central Hematology Laboratory, Cantonal Hospital of Lucerne and University of Bern, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-0949","authenticated-orcid":false,"given":"Bernhard","family":"Gerber","sequence":"additional","affiliation":[{"name":"8Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Vishnu","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-4351","authenticated-orcid":false,"given":"Lukas","family":"Graf","sequence":"additional","affiliation":[{"name":"10Cantonal Hospital of St. Gallen, St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-7135","authenticated-orcid":false,"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland"},{"name":"12University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamam","family":"Bakchoul","sequence":"additional","affiliation":[{"name":"13Centre for Clinical Transfusion Medicine, University Hospital of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4319-2367","authenticated-orcid":false,"given":"Michael","family":"Nagler","sequence":"additional","affiliation":[{"name":"1Department of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland"},{"name":"12University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"5","key":"2025111015070138200_bib1","doi-asserted-by":"crossref","first-page":"100283","DOI":"10.1016\/j.rpth.2023.100283","article-title":"Heparin induced thrombocytopenia: an illustrated review","volume":"7","author":"May","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2025111015070138200_bib2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/M22-0118","article-title":"The epidemiology of thrombosis with thrombocytopenia syndrome: analogies with heparin-induced thrombocytopenia","volume":"175","author":"Warkentin","year":"2022","journal-title":"Ann Intern Med"},{"key":"2025111015070138200_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/9781119665885.ch16","volume-title":"Practical Transfusion Medicine","author":"Warkentin","year":"2022","edition":"1st ed"},{"key":"2025111015070138200_bib4","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/bjh.18120","article-title":"Managing argatroban in heparin-induced thrombocytopenia: a retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia","volume":"197","author":"Marchetti","year":"2022","journal-title":"Br J Haematol"},{"key":"2025111015070138200_bib5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/ALN.0000000000004090","article-title":"Heparin-induced thrombocytopenia: perioperative diagnosis and management","volume":"136","author":"Koster","year":"2022","journal-title":"Anesthesiology"},{"key":"2025111015070138200_bib6","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"key":"2025111015070138200_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2025111015070138200_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jvsv.2022.12.030","article-title":"The thresholds of Caprini score associated with increased risk of venous thromboembolism across different specialties: a systematic review","volume":"11","author":"Lobastov","year":"2023","journal-title":"J Vasc Surg Venous Lymphatic Disord"},{"key":"2025111015070138200_bib9","doi-asserted-by":"crossref","first-page":"837629","DOI":"10.3389\/fimmu.2022.837629","article-title":"Immune-mediated platelet activation in COVID-19 and vaccine-induced immune thrombotic thrombocytopenia","volume":"13","author":"Uzun","year":"2022","journal-title":"Front Immunol"},{"key":"2025111015070138200_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12185-022-03516-4","article-title":"Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder","volume":"117","author":"Venier","year":"2023","journal-title":"Int J Hematol"},{"key":"2025111015070138200_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/hematology.2021000298","article-title":"COVID-19 and thrombosis: searching for evidence","volume":"2021","author":"Thilagar","year":"2021","journal-title":"Hematology"},{"key":"2025111015070138200_bib12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1055\/s-0037-1602664","article-title":"Heparin-induced thrombocytopenia in cardiac surgery patients","volume":"43","author":"Pishko","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"2025111015070138200_bib13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/ajh.26194","article-title":"Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia","volume":"96","author":"Nilius","year":"2021","journal-title":"Am J Hematol"},{"key":"2025111015070138200_bib14","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/jth.14587","article-title":"The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia","volume":"17","author":"Pishko","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2025111015070138200_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"key":"2025111015070138200_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0002-9343(99)00124-2","article-title":"Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia","volume":"106","author":"Wallis","year":"1999","journal-title":"Am J Med"},{"key":"2025111015070138200_bib17","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2011-11-376293","article-title":"How I treat heparin-induced thrombocytopenia","volume":"119","author":"Cuker","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2025111015070138200_bib18","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch Intern Med"},{"key":"2025111015070138200_bib19","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/s-0040-1712957","article-title":"Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature","volume":"120","author":"Gruel","year":"2020","journal-title":"Thromb Haemost"},{"key":"2025111015070138200_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.24759","article-title":"Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia","volume":"92","author":"Kuter","year":"2017","journal-title":"Am J Hematol"},{"key":"2025111015070138200_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1160\/TH04-12-0825","article-title":"Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients","volume":"94","author":"Greinacher","year":"2005","journal-title":"Thromb Haemost"},{"key":"2025111015070138200_bib22","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/jth.12592","article-title":"Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia","volume":"12","author":"Joseph","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2025111015070138200_bib23","doi-asserted-by":"crossref","first-page":"101745","DOI":"10.1016\/j.eclinm.2022.101745","article-title":"A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: a prospective, multicenter, observational study","volume":"55","author":"Nilius","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"9","key":"2025111015070138200_bib24","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.jtha.2023.05.016","article-title":"Limited concordance of heparin\/platelet factor 4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study","volume":"21","author":"Hammerer-Lercher","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2025111015070138200_bib25","doi-asserted-by":"crossref","first-page":"e243786","DOI":"10.1001\/jamanetworkopen.2024.3786","article-title":"Accuracy of diagnosing heparin-induced thrombocytopenia","volume":"7","author":"Larsen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025111015070138200_bib26","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1182\/bloodadvances.2024012782","article-title":"Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia","volume":"8","author":"Nilius","year":"2024","journal-title":"Blood Adv"},{"key":"2025111015070138200_bib27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2025111015070138200_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/molecules22040617","article-title":"Functional assays in the diagnosis of heparin-induced thrombocytopenia: a review","volume":"22","author":"Minet","year":"2017","journal-title":"Molecules"},{"key":"2025111015070138200_bib29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1160\/TH16-03-0240","article-title":"Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia","volume":"116","author":"Nagler","year":"2016","journal-title":"Thromb Haemost"},{"key":"2025111015070138200_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ijlh.13564","article-title":"Diagnosing heparin-induced thrombocytopenia: the need for accuracy and speed","volume":"43","author":"Pishko","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"2025111015070138200_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2019.11.004","article-title":"Accuracy of heparin-induced platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia","volume":"185","author":"Brodard","year":"2020","journal-title":"Thromb Res"},{"key":"2025111015070138200_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2021.04.017","article-title":"Accuracy of the functional, flow cytometer-based Emo-Test HIT Confirm\u00ae for the diagnosis of heparin-induced thrombocytopenia","volume":"203","author":"Brodard","year":"2021","journal-title":"Thromb Res"},{"key":"2025111015070138200_bib33","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jth.14749","article-title":"Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies","volume":"18","author":"Vayne","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2025111015070138200_bib34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.12059","article-title":"Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition","volume":"159","author":"Watson","year":"2012","journal-title":"Br J Haematol"},{"key":"2025111015070138200_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1537-2995.1994.34594249047.x","article-title":"Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4\/heparin enzyme-linked immunosorbent assay","volume":"34","author":"Greinacher","year":"1994","journal-title":"Transfusion"},{"key":"2025111015070138200_bib36","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1055\/s-0038-1646493","article-title":"A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia","volume":"66","author":"Greinacher","year":"1991","journal-title":"Thromb Haemost"},{"key":"2025111015070138200_bib37","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.3390\/jcm9072212","article-title":"Pathophysiology and diagnosis of drug-induced immune thrombocytopenia","volume":"9","author":"Vayne","year":"2020","journal-title":"JCM"},{"key":"2025111015070138200_bib38","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5546\/2418939\/blooda_adv-2025-016639-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5546\/2418939\/blooda_adv-2025-016639-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T20:07:14Z","timestamp":1762805234000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5546\/546475\/Outcomes-of-patients-with-suspected-heparin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":38,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016639","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,10,31]]}}}